Keros Therapeutics, Inc. Common Stock
KROSKeros Therapeutics, Inc. (KROS) is a biotechnology company focused on the development of novel therapeutics aimed at addressing hematologic and neurodegenerative disorders. The company specializes in targeting cytokine pathways to develop treatments that modulate hematopoiesis and neurobiology, with an emphasis on improving patient outcomes through innovative drug discovery and development.
Company News
Keros Therapeutics completed its cash tender offer to repurchase up to 10,950,165 shares of common stock at $17.75 per share, totaling approximately $194.4 million. More shares were tendered than the company could purchase, resulting in a pro-rata allocation.
Keros Therapeutics completed a cash tender offer to repurchase up to 10,950,165 shares of its common stock at $17.75 per share, totaling approximately $194.4 million. More shares were tendered than the target, so shares will be accepted on a pro rata basis.
Stay updated on Wall Street news with our daily podcast available on Seeking Alpha, iTunes, and Spotify.
Keros Therapeutics, Inc. (KROS) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
The company appointed a new director and an analyst reiterated his position on the stock.
